Lupin Names Industry Veteran Abdelaziz Toumi as CEO of LMS

Lupin’s newly formed subsidiary, Lupin Manufacturing Solutions (LMS), focuses on the development, manufacture, and sale of active pharmaceutical ingredients (API).

Global pharmaceutical company Lupin has appointed Abdelaziz Toumi as the CEO of its newly established subsidiary, Lupin Manufacturing Solutions (LMS).

Toumi, a seasoned leader with over two decades of experience in the biotech, pharma, and CDMO sectors across Europe, North America, and Asia, has joined the company, Lupin confirmed in a regulatory filing.

Lupin’s newly formed subsidiary, Lupin Manufacturing Solutions (LMS), focuses on the development, manufacture, and sale of active pharmaceutical ingredients (API).

Additionally, LMS is expanding its operations to include a contract development and manufacturing organization (CDMO) business.

Sharing thoughts on the appointment, Nilesh Gupta, MD, Lupin, said, "He brings a wealth of knowledge and experience in the API, CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers."

Toumi’s extensive career experience includes leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma.

According to the announcement, he will be based in Switzerland, with significant responsibilities in India.

Toumi holds a Doctorate in Chemical Engineering and a Master's degree in Business Administration from the University of Southern Queensland, the filing said.

Lupin is the third-largest pharmaceutical company in the US on the basis of prescriptions and runs 15 manufacturing sites and seven research centers globally.

In September 2023, Lupin carved out a business transfer agreement with LMS to transfer two API manufacturing sites and select R&D operations to the company.

Founded in 1968, the Indian multinational pharmaceutical company offers a diverse portfolio of branded and generic formulations, biotechnology products, and APIs.

Lupin serves over 100 markets spanning the US, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East. Lupin's key focus areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis.

Lupin’s Noteworthy Initiatives

Days back, Lupin Limited’s European unit, Lupin Atlantis Holdings SA, completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands from Sanofi.

Lupin highlighted that acquiring these brands is a strategic step to boost its respiratory business in Germany. Aarane (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) treats sudden asthma attacks and prevents exercise-induced asthma.

In a related development, Lupin Digital Health, a prominent player in the digital health sector, announced a significant achievement for its Lyfe platform. The platform secured approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO).

In addition to the Class C Medical Device license for the Lyfe platform, Lupin Limited, the parent company, has launched Bromfenac Ophthalmic Solution, 0.075%, following the United States Food and Drug Administration (US FDA) approval.

Last year, Lupin introduced several patient engagement programs in the digital health space. 'Humrahi, a patient support program, focuses on helping patients manage diabetes, while Jeet promotes heart health by offering cost-effective medical solutions, disease counseling, medication reminders, and lifestyle guidance.